How does VPRIV work?
How VPRIV works. VPRIV is designed to replace the deficient enzyme (glucocerebrosidase) that patients with type 1 Gaucher lack. It has the same amino acid sequence as the naturally produced enzyme that occurs in your body. In clinical trials, some patients experienced hypersensitivity, or a serious allergic reaction.
How do you administer VPRIV?
Important Administration Instructions Administer the diluted VPRIV solution through an in-line low protein-binding 0.2 or 0.22 μm filter over 60 minutes. Do not infuse VPRIV with other products in the same infusion tubing because the compatibility of a VPRIV solution with other products has not been evaluated.
How is VPRIV made?
VPRIV is made in a human cell line using Shire’s gene activation technology. The enzyme produced has the exact human amino acid sequence as that found in the naturally occurring human enzyme. VPRIV is used for the long-term treatment of patients with type 1 Gaucher disease.
When was VPRIV approved?
Development Timeline for VPRIV
| Date | Article |
|---|---|
| Feb 26, 2010 | Approval FDA Approves VPRIV to Treat Gaucher Disease |
| Nov 4, 2009 | FDA Grants Priority Review for Shire’s velaglucerase alfa for Type 1 Gaucher Disease |
Who manufactures vpriv?
Velaglucerase alfa, sold under the brand name Vpriv and manufactured by Shire plc, is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase indicated as a long-term enzyme replacement therapy for those suffering of Gaucher disease Type 1.
What does vpriv stand for?
VPRIV. (velaglucerase alfa for injection) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease (1).
Who makes elelyso?
ELELYSO ® (taliglucerase alfa) for injection is made by the Israeli biotherapeutics company Protalix.
At what age is Gaucher disease diagnosed?
This analysis reported that 48% were diagnosed before the age of 6 years; 68% were diagnosed between the ages of 0 and 10 years; and 56% were diagnosed between the ages of 10 and 20 years. The age at onset of Gaucher disease can also be affected by specific genotypes (Figure 1).